6 abstracts du LYSA-LYSARC à l'EHA 2026

Retrouvez les 6 abstracts LYSA-LYSARC dans les lymphomes et les leucémies lymphoïdes chroniques (LLC) qui seront présentés à l'EHA (European Hematology Association) du 11 au 14 juin 2026

• Poster — “Real world efficacy and safety comparison of salvage regimens combining brentuximab vedotin and chemotherapy in second-line Hodgkin lymphoma: a LYSA multicenter retrospective study”
  Abstract EHA PF922
• Poster — “Reclass: refinement of marginal zone lymphoma classification and staging improves prognostic discrimination in the prospective REALYSA cohort”
  Abstract EHA PF932
• Oral Presentation — “Development and validation of CAR-IPI, a machine learning–derived Prognostic score for relapsed/refractory large b-cell lymphoma treated with anti-cd19 CAR-T cells”
  Abstract EHA PF978
• Oral Presentation — “Radiotherapy as bridging, salvage or consolidation strategy in CAR-T–treated lymphoma patients: insights from the French DESCAR-t registry”
• Oral Presentation — “Prognostic value of PET parameters in patients with relapsed or refractory follicular lymphoma treated with lisocabtagene maraleucel (liso-cel): results from the TRANSCEND FL trial”
  
• Oral Presentation — “Contemporary treatment and survival outcomes in 1,101 follicular lymphoma patients included in REALYSA, a prospective real-world Multicentric LYSA cohort”